MedTrace Logo

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

NCT02676154 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-09-09

No results posted yet for this study

Summary

This study will be investigating the effects of fesoterodine on autonomic dysreflexia (AD) in patients with spinal cord injuries (SCI). The goal of the study is to examine the effect of increasing daily use of fesoterodine on episodes of high blood pressure triggered by urinary bladder contractions.

Conditions

  • Autonomic Dysreflexia

Interventions

DRUG

Fesoterodine

4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • International Collaboration on Repair Discoveries

    collaborator OTHER

  • Vancouver Coastal Health

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Andrei Krassioukov, MD,PhD,FRCPC · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-25
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02676154 on ClinicalTrials.gov